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Abstract
Background: A variety of arginine-rich peptide sequences similar to those found in viral proteins
have been conjugated to other molecules to facilitate their transport into the cytoplasm and
nucleus of targeted cells. The selective high affinity ligand (SHAL) (DvLPBaPPP)2LLDo, which was
developed to bind only to cells expressing HLA-DR10, has been conjugated to one of these peptide
transduction domains, hexa-arginine, to assess the impact of the peptide on SHAL uptake and
internalization by Raji cells, a B-cell lymphoma.
Results:  An analog of the SHAL (DvLPBaPPP)2LLDo containing a hexa-arginine peptide was
created by adding six D-arginine residues sequentially to a lysine inserted in the SHAL's linker.
SHAL binding, internalization and residualization by Raji cells expressing HLA-DR10 were
examined using whole cell binding assays and confocal microscopy. Raji cells were observed to bind
two fold more 111In-labeled hexa-arginine SHAL analog than Raji cells treated with the parent
SHAL. Three fold more hexa-arginine SHAL remained associated with the Raji cells after washing,
suggesting that the peptide also enhanced residualization of the 111In transported into cells.
Confocal microscopy showed both SHALs localized in the cytoplasm of Raji cells, whereas a
fraction of the hexa-arginine SHAL localized in the nucleus.
Conclusion:  The incorporation of a hexa-D-arginine peptide into the linker of the SHAL
(DvLPBaPPP)2LLDo enhanced both the uptake and residualization of the SHAL analog by Raji cells.
In contrast to the abundant cell surface binding observed with Lym-1 antibody, the majority of
(DvLPBaPPP)2LArg6AcLLDo and the parent SHAL were internalized. Some of the internalized
hexa-arginine SHAL analog was also associated with the nucleus. These results demonstrate that
several important SHAL properties, including uptake, internalization, retention and possibly
intracellular distribution, can be enhanced or modified by conjugating the SHALs to a short
polypeptide.
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Background
Several strategies have been used to selectively deliver
toxic chemicals or radiation to cancer cells [1,2], for gene
therapy [3,4] or as tools for transfecting cells [5] and
silencing genes [6]. Some of the earliest approaches used
to enhance the cellular uptake of therapeutics and other
molecules (fluorescent dyes, enzymes, antibodies and
other proteins) involved introducing the molecules into
liposomes or micelles [7,8]. Such constructs have been
shown to fuse with the cell's membrane, introducing the
contents inside the cell or transferring the lipid-bound
components into the cell's membrane. Another highly
successful approach has been to develop antibodies that
target cell-specific membrane proteins and to use these
antibodies to deliver radionuclides or other cytotoxic
molecules to the surface of a specific population of cells
[9-11]. More recently, intracellular delivery has been
accomplished by attaching the molecules to be trans-
ported to naturally occurring transmembrane "shuttles",
peptides or proteins that readily pass through cellular
membranes. One of the more successful shuttles is a
nuclear localization signal peptide derived from the SV40
T antigen [12]. This sequence, other peptide sequences
derived from the transduction domain of the HIV-1 pro-
tein Tat [13,14], penetratin [15], and intact proteins such
as the herpes virus protein VP22 [16] and anti-DNA anti-
bodies [17] are currently being used to facilitate the trans-
port of liposomes, viruses, enzymes, antibodies and a
variety of other proteins into cells. Considerable success
has also been achieved using synthetic cationic peptide
transporters such as oligoarginine [18-21], lactosylated
poly-L-lysine [22] and short peptide sequences selected
from phage display libraries [23] that exhibit sequence
similarities to know peptide shuttles.
Recently, several small molecule antibody mimics that
show promise as targeting agents for cancer imaging or
therapy have been synthesized [24-28]. In addition to
exhibiting selectivities and affinities (nM to pM) similar
to antibodies, these molecules have the potential to min-
imize some of the difficulties associated with the use of
protein-based drug delivery systems. They retain the more
desirable pharmacokinetic properties of small molecules,
are less likely to be immunogenic, may prove stable
enough for oral delivery, and the costs associated with
producing the drug can be reduced significantly. The
SHAL family of antibody mimics can also be easily modi-
fied to carry radioactive metals, a variety of tags that ena-
ble their use as imaging agents, and other small molecules
(e.g. toxins or inhibitors). Another potentially useful
modification includes alterations that facilitate uptake
and internalization of the SHAL by the targeted cell,
which would be expected to both increase tumor resi-
dence time and deliver the SHAL into an environment
(the cytoplasm or nucleus) where it could cause addi-
tional damage.
Working with a SHAL developed previously for targeting
HLA-DR10, an abundant cell surface receptor over-
expressed on B-cell malignancies, we synthesized a pep-
tide analog to the SHAL by conjugating it to hexa-
arginine, a peptide that has been demonstrated previously
to facilitate the transport of proteins and nucleic acids into
cells. Binding studies conducted with the SHAL and its
hexa-arginine analog in vitro using HLA-DR10 expressing
Raji cells show that the hexa-arginine sequence changed
the SHALs properties significantly, enhancing both SHAL
internalization and radionuclide residualization.
Results
SHAL Design and Synthesis
Two forms of the free amine SHAL, (DvLPBaPPP)2LLA,
and the hexa-arginine analog, (DvLPBaPPP)2LArg6AcLLA,
were synthesized in multi-milligram amounts and puri-
fied by high performance liquid chromatography (HPLC).
A biotin was attached to the ε-amino group of the termi-
nal amine (A) on both (DvLPBaPPP)2LLA and (DvLP-
BaPPP)2LArg6AcLLA to produce biotinylated forms for use
in cell and protein binding experiments. 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)
was attached to both (DvLPBaPPP)2LLA and (DvLP-
BaPPP)2LArg6AcLLA at the same site to enable the SHALs
to be labeled with 111In. The DOTA SHAL (DvLP-
BaPPP)2LLDo and the hexa-arginine SHAL analog (DvLP-
BaPPP)2LArg6AcLLDo (Figure 1) were labeled with 111In
at high efficiency (>90%) with specific activities ranging
from 70–85 μCi/μg SHAL. Analyses of the resulting radi-
olabeled SHAL by HPLC and cellulose acetate electro-
phoresis (CAE) showed the purity of the product to be
greater than 90%. D-isomers of arginine incorporated
during the synthesis of the hexa-arginine sequence in
(DvLPBaPPP)2LArg6AcLLDo were used to minimize the
proteolytic susceptibility of the peptide. While more
detailed experiments need to be carried out to adequately
assess the stability of the SHAL in vivo, data obtained from
one preliminary CAE experiment showed no evidence of
degradation when the hexa-D-arginine SHAL analog was
incubated in human plasma at 37°C for 24 hrs (data not
shown).
SHAL Affinity for HLA-DR10 Protein
Surface Plasmon resonance binding studies were con-
ducted with both SHALs to estimate and compare the
affinity of the two SHALs for isolated HLA-DR10 protein.
In a series of kinetic experiments in which biotinylated
versions of the SHALs were immobilized on the surface of
a streptavidin chip, the parent SHAL (DvLPBaPPP)2LLDo
was observed to bind to HLA-DR10 with a Kd ~21 nM. AMolecular Cancer 2009, 8:25 http://www.molecular-cancer.com/content/8/1/25
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similar Kd, ~34 nM, was obtained for the hexa-arginine
containing analog (DvLPBaPPP)2LArg6AcLLDo.
Analysis of SHAL Uptake by Raji Cells Expressing HLA-
DR10
In vitro cell binding experiments were conducted using
111In-labeled parent SHAL and the hexa-arginine SHAL
analog to quantify SHAL uptake and to evaluate the effect
of adding the hexa-arginine tag. Uptake was assessed
using Raji cells, a lymphoma cell line expressing HLA-
DR10. Aliquots containing 106 cells were incubated with
increasing amounts of SHAL containing 111In labeled
SHAL as a tracer, and cell-associated 111In was measured
before and after washing the cell pellets.
Analyses of the unwashed cell pellets showed that both
the parent SHAL and the hexa-arginine SHAL are bound
by Raji cells. Cell associated SHAL increased linearly with
increasing SHAL concentration in the media for both
SHALs (Figure 2), and the amount of bound SHAL
showed no evidence of reaching saturation over the range
of SHAL concentration tested. Raji cells treated with the
hexa-arginine SHAL, in contrast to those treated with the
parent SHAL, bound twice as much SHAL (Table 1). A
larger proportion of the hexa-arginine SHAL (67%) was
also retained by the cells after washing when compared to
the parent SHAL (~46%), leading to a final hexa-arginine
SHAL content three times that of its parent.
SHAL Localization by 3-D Confocal Microscopy
Fluorescence images collected at focal planes near the
center of Raji cells treated with biotinylated forms of the
parent and hexa-arginine SHALs for only an hour con-
firmed that both SHALs were taken up by Raji cells (Figure
3). In contrast to Lym-1 antibody, which binds to HLA-
DR10 on the cell surface, the sectioned images taken from
the center of the cells showed that both SHALs were local-
ized inside Raji cells and distributed throughout the cyto-
plasm. Raji cells took up significantly more of the hexa-
arginine SHAL than the parent SHAL, as evidenced by the
more intense staining of the cytoplasm of cells treated
with equivalent concentrations of the two SHALs. SHAL
Chemical structures of the dimeric SHAL (DvLP- BaPPP)2LLDo (A) and the hexa-arginine analog (DvLP- BaPPP)2LArg6AcLLDo (B) Figure 1
Chemical structures of the dimeric SHAL (DvLP-
BaPPP)2LLDo (A) and the hexa-arginine analog 
(DvLPBaPPP)2LArg6AcLLDo (B).
Binding of 111In radiolabeled SHAL (DvLPBaPPP)2LLDo and  its hexa-arginine analog (DvLPBaPPP)2LArg6AcLLDo to Raji  cells Figure 2
Binding of 111In radiolabeled SHAL (DvLP-
BaPPP)2LLDo and its hexa-arginine analog (DvLP-
BaPPP)2LArg6AcLLDo to Raji cells. Total 111In- 
(DvLPBaPPP)2LArg6AcLLDo bound to Raji cells (unwashed), 
solid squares; total 111In-(DvLPBaPPP)2LLDo bound to Raji 
cells (unwashed), open squares. Cell pellets containing 106 
cells were resuspended in 150 μl 5%BSA/PBS buffer contain-
ing 0–25 ng of 111In labeled SHAL and incubated at RT for 1 
hour. The samples were centrifuged to separate the cells 
from the supernatant and both were counted in a calibrated 
gamma well counter to quantify bound and unbound SHAL. 
Error bars are included for each data point, but in the major-
ity of the cases the error is smaller than the data point and 
the error bar is not visible.Molecular Cancer 2009, 8:25 http://www.molecular-cancer.com/content/8/1/25
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uptake was not observed in control Jurkat's cells (cells
lacking HLA-DR10). A fraction of the hexa-arginine SHAL
also appeared to be associated with the nucleus. Nuclear
staining was not observed in cells treated with the parent
SHAL.
Discussion
Numerous cell penetrating peptides (CPPs) derived from
viral and other proteins that traverse cell and nuclear
membranes have been employed as shuttles to improve
the efficiency of transport of liposomes, exogenous pro-
teins and nucleic acids, and other molecules into the cyto-
plasm and nuclei of cells [13-23]. Studies characterizing
the efficiency of internalization of different CPP
sequences, all of which have a high content of arginine
residues [29], have shown that arginine homopolymers
containing as few as six arginine residues are highly effec-
tive in transporting small organic molecules [30,31] and
large proteins into cells [32].
In an effort to develop SHALs that are more efficiently
internalized and residualized by the cells they target, we
synthesized a hexa-arginine conjugate of (DvLP-
BaPPP)2LLDo, a SHAL containing the two ligands dabsyl-
valine (Dv) and N-benzoyl-L-arginyl-4-amino benzoic
acid (Ba) that had been shown previously to bind selec-
tively to HLA-DR10 expressing cell lines [24]. Hexa-
arginine was chosen as the first shuttle sequence to be
tested for its ability to facilitate the transport of SHALs
into cells because it could be conjugated to a dimeric
SHAL without changing its molecular mass significantly,
thereby preserving the desirable properties of the SHAL as
a small molecule therapeutic. Surface Plasmon resonance
experiments comparing the binding of the SHAL and the
hexa-arginine SHAL analog to purified HLA-DR10 protein
showed that the addition of the hexa-arginine peptide to
the dimeric SHAL did not interfere with SHAL binding to
the protein.
3-D Confocal microscopy experiments revealed that both
the parent SHAL and its hexa- arginine analog were taken
up and internalized by HLA-DR10 expressing Raji cells.
SHAL uptake was not observed in Jurkat's cells, a cell line
lacking HLA-DR10. Optical sections taken through Raji
cells showed that the binding of the SHALs was not con-
fined to the cell surface, as is characteristic of Lym-1 anti-
body binding. Mid-plane sections taken from cells treated
with the SHALs showed the SHAL-associated fluorescence
to be distributed throughout the interior of the cells. In
some images, areas of high SHAL concentration within
the cytoplasm occasionally appeared to be associated with
small organelle-like structures. The cytoplasm-associated
fluorescence was significantly higher in Raji cells treated
with the hexa-arginine SHAL analog, suggesting the addi-
tion of the hexa-arginine peptide enhanced cell uptake of
the SHAL.
Experiments comparing the binding of 111In-labeled
(DvLPBaPPP)2LLDo and (DvLPBaPPP)2LArg6AcLLDo to
live Raji cells confirmed that the hexa-arginine tag
enhanced SHAL uptake. The presence of the tag also
increased the amount of 111In-labeled SHAL that was
retained by Raji cells. The amount of SHAL retained after
washing did not reach saturation over the concentration
range tested, suggesting that even higher concentrations of
SHAL may be accumulated inside HLA-DR10 expressing
cells than achieved in these experiments. At the highest
concentration of hexa-arginine SHAL tested in the cell
binding studies, the amount of residualized SHAL was
equivalent to ~1.1 × 106 SHAL molecules per cell – the
same number of HLA-DR10 molecules reported previ-
ously to be present on the surface of each Raji cell [33].
These results, together with the confocal images showing
the majority of the hexa-arginine SHAL is internalized,
indicate that a significant fraction of the SHAL may be
bound to the pool of HLA-DR10 known to be present
inside the cell.
The observed enhancement in residualization of 111In-
labeled hexa-arginine SHAL by Raji cells and the potential
association of a fraction of the 111In-label with the nucleus
are also important because radioisotope internalization
and residualization have been shown to be highly advan-
tageous for cancer therapy [34-37]. Cancer therapeutics
have been linked to a variety of radioisotopes that emit
beta particles, alpha particles or Auger electrons. The
Table 1: Retention (residualization) of bound SHAL by Raji cells.
pmoles SHAL Bound/106 cells Percent SHAL Retained
SHAL Unwashed Washed
(DvLPBaPPP)2LLDo 0.568 ± 0.091 0.263 ± 0.000 46
(DvLPBaPPP)2LArg6AcLLDo 1.300 ± 0.038 0.876 ± 0.017 67
Identical samples of cells used in experiments shown in Figure 2 were incubated as described in the Materials and Methods with 5.3 pmoles of 111In-
labeled (DvLPBaPPP)2LLDo or (DvLPBaPPP)2LArg6AcLLDo and then washed two times with BSA/buffer. The cell pellets were then counted to 
provide estimates of SHAL remaining bound after washing.Molecular Cancer 2009, 8:25 http://www.molecular-cancer.com/content/8/1/25
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range of beta emissions from isotopes routinely used in
radioimmunotherapy, such as iodine-131, yttrium-90,
and rhenium-188, extend for several millimeters, and
therapeutics carrying these radionuclides create a "cross-
fire" [1,38] or "bystander" [39] effect destroying malig-
nant cells to which the targeting agent is not directly
bound. In this way, beta-emitters can potentially over-
come resistance due to antigen-negative tumor cells.
These characteristics make beta-particle therapy better
suited for treating bulky tumors or large-volume disease.
However, longer-ranged beta emissions can also destroy
nearby normal cells.
The internalization of targeting agents such as the hexa-
arginine SHAL (DvLPBaPPP)2LArg6AcLLDo can be
exploited as a means of introducing Auger electron-emit-
ting 111In into the cytoplasm and nucleus of cells where
the Auger electrons have a very short, subcellular path
length and high linear energy transfer [40-42]. The radia-
tion absorbed dose to the nucleus has been estimated to
be 2-fold and 35-fold greater when 111In decays in the
nucleus compared to when decay occurs in the cytoplasm
or on the cell surface, respectively [43,44]. These proper-
ties render 111In and other Auger electron-emitters highly
cytotoxic and damaging to DNA when they decay in close
proximity to the cell nucleus [45]. By coupling Auger
emitters to highly selective, residualizing targeting agents
that accumulate to high concentrations inside tumor cells,
a very powerful class of therapeutics may be developed
that are more effective in treating many types of metastatic
cancer.
Conclusion
The enhancement in hexa-arginine SHAL internalization
by HLA-DR10 expressing lymphoma cells and the magni-
tude of the increase in SHAL residualization achieved by
conjugating a hexa-arginine peptide to the SHAL are
important because they show that small molecules such as
SHALs can be designed to deliver radionuclides to malig-
nant cells under conditions that lead to residualization of
significant concentrations of radionuclide inside the cell.
If additional studies confirm that hexa-arginine or other
peptide SHAL analogs accumulate near or inside the
nucleus, SHALs carrying Auger-emitting radionuclides
may provide an alternative approach for increasing the
therapeutic index achieved with SHALs beyond that
attained by the accumulation of radionuclide-tagged tar-
geting agents on the surface of the tumor cell. These
results are also exciting because of the relevance of the
SHAL-based approach to treating other forms of cancer.
Internalizing SHALs targeting under-glycosylated MUC1,
the androgen receptor and other tumor specific cell sur-
face proteins that residualize the radioisotopes they carry
could also be developed as small molecule therapeutics
for a wide variety of other types of metastatic cancer.
Fluorescent 3-D confocal microscopy of parent SHAL  (DvLPBaPPP)2LLDo (top row) binding to live Raji cells com- pared to the hexa-arginine analog (DvLP- BaPPP)2LArg6AcLLDo (middle row) Figure 3
Fluorescent 3-D confocal microscopy of parent 
SHAL (DvLPBaPPP)2LLDo (top row) binding to live 
Raji cells compared to the hexa-arginine analog 
(DvLPBaPPP)2LArg6AcLLDo (middle row). Two mid-
cell focal planes within the Raji cells are shown (left to right). 
Jurkat's cells treated with (DvLPBaPPP)2LArg6AcLLDo (left 
panel, bottom row) show minimal SHAL uptake. Lym-1 (right 
panel, bottom row) exhibits primarily cell surface membrane 
binding to Raji cells. The parent SHAL shows intracellular 
binding, while the hexa-arginine analog demonstrates not 
only marked cytoplasmic binding but also intranuclear target-
ing. DAPI (blue) is used as the nuclear stain and AlexaFlor 
610 (red) demonstrates the location of SHAL in these 
merged sequential laser images.Molecular Cancer 2009, 8:25 http://www.molecular-cancer.com/content/8/1/25
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Methods
SHAL Design, Synthesis, and Radiochemistry
Design
The process used to create a homology model for HLA-
DR10, identify unique binding cavities within the Lym-1
epitope, select ligands that bind in these cavities, and cre-
ate the (DvLPBaPPP)2LLDo SHAL has been reported pre-
viously [24]. A process for producing a hexa-arginine
peptide analog of this parent SHAL, (DvLP-
BaPPP)2LArg6AcLLDo, was developed by modifying the
synthesis to include the incorporation of an additional
lysine residue into the middle of the linker connecting the
two SHAL monomers and attaching an arginine hexapep-
tide to the free amine on this lysine.
Synthesis
The two dimeric SHALs (DvLPBaPPP)2LLA and (DvLP-
BaPPP)2LArg6AcLLA were synthesized on chlorotrityl
chloride resin using orthogonally protected lysine (L) res-
idues and miniPEGs (P) to link the two small ligands Dv
and Ba as previously described for (DvLPBaPPP)2LLA
[24,46]. To produce the amine derivative of the hexa-
arginine SHAL (DvLPBaPPP)2LArg6AcLLA, a second Dde-
D-Lys(Fmoc)-OH lysine residue was inserted into the
linker during SHAL synthesis by performing two sequen-
tial Dde-D-Lys(Fmoc)-OH coupling steps. At the alpha
position of the third lysine, six consecutive arginine resi-
dues were inserted by reacting the resin with Fmoc-D-
Arg(Pbf)-OH six times. The sixth Arg residue was pro-
tected with an acetate (Ac) by reacting with acetic anhy-
dride in N, N diisopropyl-ethylamine (DIEA)/
dimethylformamide (DMF). The guanidinium groups on
all six arginine residues remain protected with trifluoro-
acetic acid (TFA)-sensitive 2,2,4,6,7-Pentamethyldihyd-
robenzofuran-5-sulfonyl (Pbf) protecting groups
throughout the rest of the synthesis. The remainder of the
synthesis was then completed as described previously for
(DvLPBaPPP)2LLA [24,46]. Analytical HPLC and electro-
spray ionization mass spectrometry (ESI-MS) were per-
formed to confirm the purity and identity of the
(DvLPBaPPP)2LLA and (DvLPBaPPP)2LArg6AcLLA free
amine SHALs.
(DvLPBaPPP)2LLA
Starting with 50 mg (0.07 mmol) resin and 30 mg (0.07
mmol) Fmoc-D-Lys(Boc)-OH, 34 mg of (DvLP-
BaPPP)2LLA (Rt = 7.86 min, Waters Symmetry C18, 5 μm,
4.2 × 150 mm column, diode array detector with a linear
gradient from 95% H2O, 1% TFA to 80% acetonitrile
(MeCN), 1% TFA over 12 min) was isolated as a red solid
after purification. ESI-MS: m/z  calculated for
C150H224N34O41S2 (M + 3H)3+ 1075.60, found 1075.62;
calculated for (M + 4H)4+ 806.95, found 806.93; calcu-
lated for (M + 5H)5+ 645.76, found 645.68; calculated for
(M + 6H)6+ 538.30, found 538.21.
(DvLPBaPPP)2LArg6AcLLA
81 mg of (DvLPBaPPP)2LArg6AcLLA (Rt = 8.30 min) start-
ing from 90 mg (0.12 mmol) resin and 154 mg (0.29
mmol) Fmoc-D-Lys(Boc)-OH was isolated as a red solid
after purification. ESI-MS: m/z  calculated for
C194H310N60O49S2 (M + 3H)3+ 1444.71, found 1444.65;
calculated for (M + 4H)4+ 1083.76, found 1083.78; calcu-
lated for (M + 5H)5+ 867.23, found 867.18; calculated for
(M + 6H)6+ 722.86, found 722.78; calculated for (M +
7H)7+ 619.74, found 619.62.
Attachment of DOTA to SHALs
The amine analog of the SHAL (DOTA-SHAL precursor
with a free epsilon amine on the first lysine) was dissolved
in 500 μl anhydrous DMF and 100 μl DIEA. The hex-
afluorophosphate (PF6) salt of DOTA N-hydroxysuccin-
imide (NHS) ester (933.36 g/mol, 1–1.5 equivalents) was
added to the mixture as a solid. The mixture was nutated
for 15 min and the reaction was monitored by analytical
HPLC. Upon completion the reaction solution was
diluted with 300 μl H2O and 300 μl MeCN (both contain-
ing 1% TFA) and HPLC purified using an 85% H2O (0.1%
TFA) to 70% MeCN (0.1% TFA) gradient run over 25 min.
The resulting purified DOTA-SHALs were lyophilized and
subsequently analyzed by analytical HPLC (Waters Sym-
metry C18, 5 μm, 4.2 × 150 mm column, diode array
detector) using a linear gradient from 95% H2O (1% TFA)
to 80% MeCN (1% TFA) over 12 min) and characterized
by ESI-MS.
(DvLPBaPPP)2LLDo
Reaction of the (DvLPBaPPP)2LLA amine SHAL (6.0 mg,
1.86 μmol) with DOTA NHS ester (2.0 mg, 2.14 μmol)
gave 100% (Rt = 7.664 min) conversion by crude analyti-
cal HPLC and yielded (DvLPBaPPP)2LLDo (8.0 mg, red
solid) after purification. ESI-MS: m/z calculated for
C166H250N38O48S2 (M + 2H)2+ 1806.09, found 1806.22;
calculated for (M + 3H)3+ 1204.40, found 1204.49; calcu-
lated for (M + 4H)4+ 903.55, found 903.61; calculated for
(M + 5H)5+ 723.04, found 723.07; calculated for (M +
6H)6+ 602.70, found 602.64.
(DvLPBaPPP)2LArg6AcLLDo
Reaction of (DvLPBaPPP)2LArg6AcLLA amine SHAL (15.0
mg, 3.46 μmol) with DOTA NHS ester (5.0 mg, 5.36
μmol) gave 100% (Rt = 7.70 min) conversion by crude
analytical HPLC and yielded (DvLPBaPPP)2LArg6AcLLDo
(12.0 mg, red solid) after purification. ESI-MS: m/z calcu-
lated for C210H336N64O56S2 (M + 3H)3+ 1573.51, found
1573.54; calculated for (M + 4H)4+  1180.38, found
1180.43; calculated for (M + 5H)5+ 944.51, found 944.52;
calculated for (M + 6H)6+ 787.26, found 787.26; calcu-
lated for (M + 7H)7+ 674.94, found 674.88; calculated for
(M + 8H)8+ 590.69, found 590.58.Molecular Cancer 2009, 8:25 http://www.molecular-cancer.com/content/8/1/25
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Radiochemistry
As described previously [24,26], the DOTA-SHALs were
labeled with carrier-free 111InCl3 (MDS Nordion, Vancou-
ver, Canada) using the following method [26]. An aliquot
of 111InCl3 (15–20 μl) was added to a solution of DOTA-
SHAL (25–50 μg) in 0.1 M NH4OAc, pH 5.3 (50 μl); the
final pH of the reaction mixture was adjusted to 6.5 by
adding 4 M NH4OAc and the mixture was incubated for 1
h at 37°C, then 10–20 μl of 0.1 M ethylenediamine-
tetraacetic acid (EDTA) was added to sequester excess, free
111In3+. The radiolabeled product was purified using
HPLC, followed by dialysis in phosphate-buffered saline
(PBS) with a 1 kD cut off membrane. The purity of the
111In-labeled SHALs was determined by thin layer chro-
matography (TLC) (10% NH4OAc-MeOH 1:1), HPLC and
cellulose acetate electrophoresis (CAE). CAE resolved
111In-DOTA-SHALs and 111In-EDTA; radioactive peaks
were observed at 2.3–3.0 cm and > 6.5 cm, respectively.
Similar results were observed in the TLC assay; 111In-
DOTA-SHALs showed little migration from the point of
application (RF = 0.25–0.3), whereas 111In-EDTA moved
towards the solvent front (RF = 0.5). By HPLC, 111In-EDTA
eluted at 2.5–3.0 ml and 111In-DOTA-SHALs at 9.5–10
ml. The 111In labeled SHALs were purified using RP-HPLC
or a 1 kD dialysis membrane in PBS, and concentrated
using a Savant Speedvac SC110 (Thermo Fisher Scientific,
Inc, Waltham, MA, USA). Final radiochemical purity was
determined using C18-RP-TLC (EM Science, DC-Plastik-
folien kieselgel 60 F254, Cherry Hill, NJ), HPLC, and CAE.
111In-DOTA-SHAL product yields ranged from 70 – 90%
and the purity of the product ranged from 90 – 95%. The
final product was dissolved in 10% dimethylsulfoxide
(DMSO) in PBS, and proved stable over 72 hours at room
temperature.
SHAL Binding to Isolated HLA-DR10 Protein
Protein binding experiments were conducted using sur-
face plasma resonance on a Biacore 3000 (Biacore, Piscat-
away, NJ) at 25°C. A research grade streptavidin
immobilized chip (SA chip, Biacore) was preconditioned
and normalized according to the manufacturers instruc-
tions. Biotin labeled SHALs were dissolved in DMSO and
diluted in 1.05× PBS (Biacore) to a final concentration of
1× PBS pH 7.4, 5% DMSO, to match the running buffer.
These SHALs were injected over the flow cell to yield a sur-
face density of 500–1000 RU (response units). Biotin (50
μM E-Z Link Amine-PEO2-Biotin, Pierce) was injected
over all cells for 1 minute at 20 μl/min as a block to reduce
non-specific binding. One flow cell was used as a refer-
ence cell and a different SHAL was immobilized on each
of the three other cells.
Experiments measuring the binding of HLA-DR10 to the
SHALs were carried out at a flow rate of 30 μl/minute in
PBS pH7.4 running buffer using all 4 flow cells. HLA-
DR10 isolated from Raji cells [47] was diluted in running
buffer to a final concentration ranging from 10 nM to 1
μM, and a series of concentrations were run randomly in
triplicate. Protein was injected for 3 minutes, allowed to
dissociate for 5 minutes followed by regeneration of the
surface using a 1 minute injection of 0.1% sodium
dodecylsulfate (SDS) followed by a washing step with a 2
minute injection of running buffer. The data, which were
double referenced by subtracting the blank reference sur-
face and an average of 5 blank injections, were processed
using the program SCRUBBER (University of Utah).
Cell Binding Assay
Raji human Burkitt's lymphoma B-cells (American Type
Culture Collection, Manassas, VA) were maintained in
RPMI-1640 media supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 1% of
a solution of nonessential amino acids (GIBCO #11140–
050), and 100 units/ml of Penicillin G, 100 μg/ml Strep-
tomycin, and 0.25 μg/ml of Amphotericin B at 37°C in a
humidified 5% CO2 atmosphere. Jurkat's cells (American
Type Culture Collection, Manassas, VA), an acute leuke-
mia T-cell line, were maintained in the same medium
with the addition of 10 mM 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid (HEPES).
A series of experiments were conducted to quantify the
uptake of the 111In-labeled parent SHAL (DvLP-
BaPPP)2LLDo and its hexa-arginine analog (DvLP-
BaPPP)2LArg6AcLLDo by Raji cells, a cell line that has
been previously shown to express the HLA-DR10 variant.
The assays were conducted using aliquots containing 106
cells suspended in 150 μl of PBS with 5% bovine serum
albumin (BSA). Aliquots of cells were treated with 0.1, 1,
5, 10 or 25 ng of 111In-labeled (DvLPBaPPP)2LLDo or
(DvLPBaPPP)2LArg6AcLLDo for one hour at both 4°C
and 22°C. The tubes containing the treated cells were cen-
trifuged to separate the cell pellet from the supernatant
and the two fractions were counted in a calibrated gamma
well counter to determine the amount of bound and free
SHAL. Half of the cell pellets were washed twice with PBS
and incubated at 22°C for 15 min before centrifuging
them again. The pooled washes and washed cell pellets
were subsequently counted in the gamma well counter to
assess how much of the bound SHAL could be removed
by washing.
3-D Confocal Microscopy
SHAL binding and internalization by Raji and Jurkat's
cells was assessed using the method described previously
by O'Donnell et al[48]. Experiments were conducted
comparing the binding of (DvLPBaPPP)2LLDo (the par-
ent SHAL), its hexa-arginine analog (DvLP-
BaPPP)2LArg6AcLLDo, and chimeric Lym-1 (chLym-1) to
Raji cells. All steps were performed at 20°C.Molecular Cancer 2009, 8:25 http://www.molecular-cancer.com/content/8/1/25
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Four million Raji cells (>92% viability) in log phase
growth were pelleted at 300 × g, washed, and blocked for
30 min in 1 ml of 1% fraction V BSA in PBS, with constant
rotation. Cells were then incubated 1 hr, at a concentra-
tion of 1 million cells per 250 μl, with either 1% BSA in
PBS or a biotinylated primary reagent: 10 nM chLym-1, 10
μM parent SHAL, or 10 μM hexa-arginine SHAL. After four
washes (two in 1% BSA in PBS, two in PBS), 50 μl of the
cell suspensions was applied to freshly poly-L-Lysine
coated slides, and cells were allowed to adhere for 10 min
in a humid chamber. Fixation and permeabilization were
performed at -20°C by using a 4 min exposure to metha-
nol. Jurkat's cells were treated in the same manner as a
control.
Slides were then washed twice in PBS and blocked in 10%
fetaplex serum (Gemini Bioproducts, West Sacramento,
CA) in PBS for 15 min and washed once in PBS. The detec-
tion reagent, Streptavidin AlexaFluor 610 (Invitrogen,
Carlsbad, CA) was diluted 1/500 in diluent, 100 μl was
applied; a parafilm cover slip was layered over the solu-
tion to prevent evaporation. The slides were incubated in
a humid chamber for 30 min., washed 5 times for 5 min
each in PBS, and rinsed briefly in double distilled H2O.
After the slides dried, cover slips were mounted with Pro-
longGold with 4',6-diamidino-2-phenylindole (DAPI,
Invitrogen, Carlsbad, CA). The slides were viewed with an
Olympus FV1000 laser scanning confocal microscope and
data were collected as Z-scans at 160X, with focal sections
being taken 1 μm apart through the cell.
Statistical Analysis
Data is reported as mean ± SD. Statistical comparisons
were based on the Wilcoxon rank sum test [49], a proce-
dure based on ranking the values of two test groups. Dif-
ferences were considered statistically significant if p values
were ≤ 0.05. The p-values were determined by the trans-
formation Z = TANH-1r for the correlation coefficients
[50].
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